Press Release Distribution
Pricing
Customer Support
(800) 998-2927
Login
Log In
All Categories
Business
Entertainment
Health
Finance
Other
Tagged
epx-100
Press Release
Jun 1, 2022
First Canadian Participant Dosed in ARGUS Trial, A Phase 2 Potentially Pivotal Study of EPX-100 Treatment of Dravet Syndrome
Read More
Press Release
Feb 16, 2022
Health Canada Issues No Objection Letter to Initiate the ELEGANSE Trial With EPX-100 to Treat Lennox-Gastaut Syndrome
Read More
Press Release
Aug 30, 2021
Epygenix Therapeutics Announces FDA Acceptance of IND to Initiate a Clinical Trial of EPX-100 to Treat Lennox-Gastaut Syndrome
Read More
Press Release
Aug 2, 2021
Health Canada Grants No Objection Letter to Epygenix Therapeutics to Proceed With ARGUS Trial for the Treatment of Dravet Syndrome
Read More
Press Release
Nov 12, 2020
Epygenix Therapeutics Announces First Patient Successfully Dosed in Phase 2 Study for the Treatment of Dravet Syndrome With EPX-100
Read More
Press Release
Oct 2, 2020
Epygenix Therapeutics Announces First Patient Enrolled in Phase 2 Study for the Treatment of Dravet Syndrome With EPX-100
Read More
Press Release
Sep 17, 2020
Epygenix Therapeutics Initiates Phase 2 Study for Dravet Syndrome With EPX-100
Read More
Press Release
Jan 27, 2020
Epygenix Therapeutics Successfully Completes EPX-100 Phase I, Placebo-Controlled, Double-Blind, 2-Period Study and Ready to Phase 2 Studies
Read More
Press Release
Jul 29, 2019
Epygenix Therapeutics Receives IND Approval of EPX-100 for the Treatment of Dravet Syndrome
Dravet Syndrome, a catastrophic form of epilepsy, affects one in 15,700 children and adults in the United States.
Read More
Press Release
Jun 24, 2019
Epygenix Therapeutics Submits Investigational New Drug Application for EPX-100 to the U.S. FDA for the Treatment of Patients With Dravet Syndrome
Read More
First
Prev
1
Next
Last
